* Phathom Pharmaceuticals Inc PHAT.OQ reported a quarterly
adjusted loss of $1.56 per share for the quarter ended in
June, lower than the same quarter last year, when the company
reported EPS of -84 cents. The mean expectation of
seven analysts for the quarter was for a loss of $1.38 per
share. Wall Street expected results to range from $-1.65
to $-1.28 per share.
* Revenue was $7.32 million; analysts expected $5.81
million.
* Phathom Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.56.
* The company reported a quarterly loss of $91.45 million.
* Phathom Pharmaceuticals Inc shares had risen by 5.0% this
quarter and gained 18.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7.4%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $24.00
This summary was machine generated from LSEG data August 8 at
02:40 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.38 -1.56 Missed
Mar. 31 2024 -1.31 -1.42 Missed
Dec. 31 2023 -1.08 -1.39 Missed
Sep. 30 2023 -0.89 -0.76 Beat